Division of Paediatrics, Assaf Harofeh Medical Center, Zerifin, Israel.
Arch Dis Child. 2011 Apr;96(4):345-9. doi: 10.1136/adc.2010.197459. Epub 2011 Jan 24.
Probiotics have been shown to be immunomodulatory and can affect antibody responses following vaccination. Several immunisations are associated with suboptimal seroconversion rates leaving a substantial part of the population exposed to infection.
To evaluate the influence of probiotic supplementation on the immune response of infants following mumps, measles, rubella and varicella vaccination.
A randomised, placebo-controlled, double blinded prospective trial was performed in a cohort of healthy infants. Study subjects were randomly assigned to receive probiotics or placebo for a total of 5 months, starting 2 months prior to vaccination. Antibody levels against vaccine components were measured 3 months after immunisation. Treatment-related and vaccine-related adverse events were recorded.
47 infants completed the study, 25 in the probiotic group and 22 in the placebo group. There was no statistically significant difference in the number of infants failing to reach protective antibody titres against the different vaccine components (three infants in the placebo group against one in the treatment group for rubella, two each for mumps, four children vs two for measles). When combining all results in both groups, a larger percentage of failures to seroconvert occurred in the placebo group (17% vs 8%, p=0.052), a result of borderline significance. The number of infants needed to treat in order to prevent one failed vaccine component was 12. There was no difference in the rate of treatment related adverse effects between the two groups. There was a significant trend toward fewer vaccine related adverse effects in the treatment group.
Oral probiotics given to infants during the period of immunisation do not interfere with the immune response to mumps, measles, rubella and varicella vaccine, and may improve seroconversion rates.
益生菌具有免疫调节作用，可影响疫苗接种后的抗体反应。有几种免疫接种与不理想的血清转化率有关，这使得相当一部分人群面临感染风险。
评估益生菌补充剂对接受腮腺炎、麻疹、风疹和水痘疫苗接种的婴儿免疫反应的影响。
在一组健康婴儿中进行了一项随机、安慰剂对照、双盲前瞻性试验。研究对象被随机分配接受益生菌或安慰剂治疗，共 5 个月，从接种前 2 个月开始。在免疫接种后 3 个月测量针对疫苗成分的抗体水平。记录与治疗相关和与疫苗相关的不良事件。
47 名婴儿完成了研究，其中 25 名在益生菌组，22 名在安慰剂组。在未能达到针对不同疫苗成分的保护性抗体滴度的婴儿数量方面，两组之间没有统计学上的显著差异（安慰剂组有 3 名婴儿对风疹，治疗组有 1 名婴儿，2 名婴儿对腮腺炎，4 名婴儿对麻疹，2 名婴儿）。当将两组的所有结果合并时，安慰剂组的血清转化率失败率更高（17%对 8%，p=0.052），这是一个边缘显著的结果。为了预防一个疫苗成分失败，需要治疗的婴儿数量为 12。两组之间治疗相关不良事件的发生率没有差异。治疗组疫苗相关不良事件的发生率呈显著下降趋势。
在免疫期间给予婴儿口服益生菌不会干扰腮腺炎、麻疹、风疹和水痘疫苗的免疫反应，并且可能提高血清转化率。
